Upjohn Co.’s profit rose 17% to $95...

Upjohn Co.’s profit rose 17% to $95 million in its first quarter, compared to $81 million for the same period last year. The Kalamazoo, Mich.-based pharmaceutical, agricultural products and chemical maker said the gain reflected exceptionally strong U.S. sales of Xanax and Halcion, which are used to treat depression and insomnia, and Micronase, an anti-diabetes drug. The firm said increases in foreign and agricultural sales also were significant factors.